Epidemiology of MPN: What Do We Know?

被引:0
|
作者
L. A. Anderson
M. F. McMullin
机构
[1] Queen’s University Belfast,Centre for Public Health
[2] Queen’s University Belfast,Centre for Cancer Research and Cell Biology
来源
Current Hematologic Malignancy Reports | 2014年 / 9卷
关键词
Epidemiology; Myeloproliferative neoplasms; Survival; Body mass index; Diet; Benzene;
D O I
暂无
中图分类号
学科分类号
摘要
The myeloproliferative neoplasms, are characterised by overproduction of myeloid cells. Chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia, myelofibrosis and the very rare disorders chronic neutrophilic leukaemia, chronic eosinophilic leukaemia not otherwise specified and mastocytosis are all included in the group. Incidence and prevalence rates reported in the worldwide literature are presented in this review. Survival data on each condition is described. Information on the aetiology of the disorders is discussed including body mass index, diet, smoking and alcohol, allergies, associated medical conditions, occupation and environmental exposures with focus on recent new studies. The aetiology of the myeloproliferative neoplasms remains unknown, and this review of the current state of knowledge highlights the need for further comprehensive research.
引用
收藏
页码:340 / 349
页数:9
相关论文
共 50 条
  • [1] Epidemiology of MPN: What Do We Know?
    Anderson, L. A.
    McMullin, M. F.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (04) : 340 - 349
  • [2] What is status epilepticus and what do we know about its epidemiology?
    Shorvon, Simon
    Sen, Arjune
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2020, 75 : 131 - 136
  • [3] What do we know about why women bleed and what do we not know?
    James, Andra H.
    James, Paula D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (02) : 315 - 322
  • [4] Fibromyalgia and nutrition, what do we know?
    Arranz, Laura-Isabel
    Canela, Miguel-Angel
    Rafecas, Magda
    RHEUMATOLOGY INTERNATIONAL, 2010, 30 (11) : 1417 - 1427
  • [5] Arthritis in Canada: What do we know and what should we know?
    Badley, EM
    JOURNAL OF RHEUMATOLOGY, 2005, 32 : 39 - 41
  • [6] WHAT IS A CAUSE AND HOW DO WE KNOW ONE - A GRAMMAR FOR PRAGMATIC EPIDEMIOLOGY
    SUSSER, M
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1991, 133 (07) : 635 - 648
  • [7] Psychosomatic and Psychosocial Questions Regarding Bariatric Surgery: What Do We Know, or What Do We Think We Know?
    Herpertz, Stephan
    Kessler, Henrik
    Jongen, Sebastian
    ZEITSCHRIFT FUR PSYCHOSOMATISCHE MEDIZIN UND PSYCHOTHERAPIE, 2017, 63 (04): : 344 - 369
  • [8] Effects of climate change on European ducks: what do we know and what do we need to know?
    Guillemain, Matthieu
    Poysa, Hannu
    Fox, Anthony D.
    Arzel, Celine
    Dessborn, Lisa
    Ekroos, Johan
    Gunnarsson, Gunnar
    Holm, Thomas Eske
    Christensen, Thomas Kjaer
    Lehikoinen, Aleksi
    Mitchell, Carl
    Rintala, Jukka
    Moller, Anders Pape
    WILDLIFE BIOLOGY, 2013, 19 (04) : 404 - 419
  • [9] Epidemiology of insomnia: what we know and what we still need to learn
    Ohayon, MM
    SLEEP MEDICINE REVIEWS, 2002, 6 (02) : 97 - 111
  • [10] Relationship between cigarette use and prostate cancer risk: what do we know and what should we do?
    Nolazco, Jose Ignacio
    Mucci, Lorelei. A. A.
    Sosnowski, Roman
    Przewozniak, Krzysztof
    Chang, Steven. L. L.
    De Nunzio, Cosimo
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (03) : 516 - 518